Br J Pharmacol 169(2):304-17
Publication Date: April 26, 2013
Product Type: iCell Cardiomyocytes
This review assesses state-of-the art technology as of 2013, noting the advantages, potentials, and limitations of stem cell-derived cardiomyocytes in pharmacological screening.
The data and references within this review provide readers with peer-reviewed demonstrations of stem cell-derived cardiomyocyte utility. Many of the shortcomings and/or gaps in the technology are being (or have been) addressed by CDI.